Skip to main navigation Skip to search Skip to main content

The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial

  • Pannipa Suwannasom
  • , Yohei Sotomi
  • , Yuki Ishibashi
  • , Rafael Cavalcante
  • , Felipe N. Albuquerque
  • , Carlos Macaya
  • , John A. Ormiston
  • , Jonathan Hill
  • , Irene M. Lang
  • , Mohaned Egred
  • , Jean Fajadet
  • , Maciej Lesiak
  • , Jan G. Tijssen
  • , Joanna J. Wykrzykowska
  • , Robbert J. de Winter
  • , Bernard Chevalier
  • , Patrick W. Serruys
  • , Yoshinobu Onuma
  • Erasmus MC
  • Academic Medical Center
  • Faculty of Medicine, Chiang Mai University
  • Albert Einstein College of Medicine
  • Hospital Clinico San Carlos
  • Auckland City Hospital
  • King's College Hospital
  • Medical University Vienna
  • Freeman Hospital
  • Pasteur Hospital
  • Poznan University of Medical Sciences
  • Institut Jacques Cartier
  • National Heart and Lung Institute

Research output: Contribution to a Journal (Peer & Non Peer)Articlepeer-review

92 Citations (Scopus)

Abstract

Objectives The study sought to investigate the relationship between post-procedural asymmetry, expansion, and eccentricity indices of metallic everolimus-eluting stent (EES) and bioresorbable vascular scaffold (BVS) and their respective impact on clinical events at 1-year follow-up. Background Mechanical properties of a fully BVS are inherently different from those of permanent metallic stent. Methods The ABSORB II (A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions) trial compared the BVS and metallic EES in the treatment of a de novo coronary artery stenosis. Protocol-mandated intravascular ultrasound imaging was performed pre- and post-procedure in 470 patients (162 metallic EES and 308 BVS). Asymmetry index (AI) was calculated per lesion as: (1 − minimum scaffold/stent diameter/maximum scaffold/stent diameter). Expansion index and optimal scaffold/stent expansion followed the definition of the MUSIC (Multicenter Ultrasound Stenting in Coronaries) study. Eccentricity index (EI) was calculated as the ratio of minimum and maximum scaffold/stent diameter per cross section. The incidence of device-oriented composite endpoint (DoCE) was collected. Results Post-procedure, the metallic EES group was more symmetric and concentric than the BVS group. Only 8.0% of the BVS arm and 20.0% of the metallic EES arm achieved optimal scaffold/stent expansion (p < 0.001). At 1 year, there was no difference in the DoCE between both devices (BVS 5.2% vs. EES 3.1%; p = 0.29). Post-procedural devices asymmetry and eccentricity were related to higher event rates while there was no relevance to the expansion status. Subsequent multivariate analysis identified that post-procedural AI >0.30 is an independent predictor of DoCE (hazard ratio: 3.43; 95% confidence interval: 1.08 to 10.92; p = 0.037). Conclusions BVS implantation is more frequently associated with post-procedural asymmetric and eccentric morphology compared to metallic EES. Post-procedural devices asymmetry were independently associated with DoCE following percutaneous coronary intervention. However, this approach should be viewed as hypothesis generating due to low event rates.

Original languageEnglish
Pages (from-to)1231-1242
Number of pages12
JournalJACC: Cardiovascular Interventions
Volume9
Issue number12
DOIs
Publication statusPublished - 27 Jun 2016
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • asymmetry
  • bioresorbable vascular scaffolds
  • eccentricity
  • expansion

Fingerprint

Dive into the research topics of 'The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial'. Together they form a unique fingerprint.

Cite this